A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
Denise A. Yardley
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Erika Paige Hamilton
No relevant relationships to disclose
Lowell L. Hart
No relevant relationships to disclose
Mythili Shastry
No relevant relationships to disclose
Laura M. DeBusk
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose